- Adjusted EPS: Aflac reported an adjusted EPS of $1.83, surpassing last year’s $1.58 and beating the estimate of $1.60.
- Revenue: The company’s revenue was $5.14 billion, slightly down by 0.7% year-over-year but well above the estimated $4.32 billion.
- Book Value Per Share: Aflac’s book value per share increased to $46.40 from $34.30 year-over-year, higher than the $41.67 estimate.
- US Net Premium Income: Net premium income in the US grew to $1.5 billion, a 7.1% year-over-year increase, exceeding the $1.46 billion estimate.
- US Adjusted Net Investment Income: The adjusted net investment income in the US reached $218 million, up by 7.4% year-over-year, and above the $212.4 million estimate.
- Benefits and Claims Expense: The company saw a decrease in benefits and claims expenses to $1.92 billion, an 8.4% drop year-over-year.
- Sales Increase: Aflac achieved a 4.5% sales increase for the quarter, thanks to sales campaigns celebrating its 50 years in Japan.
- New Life Insurance Product: The initial introduction of a new life insurance product, which offers asset formation and a nursing care option, received positive feedback.
- Focus on Profitable Growth: Aflac is focusing on profitable growth by implementing stronger underwriting discipline, resulting in improved net earned premiums and persistency.
- Analyst Recommendations: The stock has 3 buy ratings, 9 hold ratings, and 2 sell ratings.
Aflac Inc on Smartkarma
Analyst coverage of Aflac Inc on Smartkarma has been insightful, with Baptista Research shedding light on key aspects of the company’s performance. In their report titled “Aflac Incorporated: Strategic Sales Execution & Diverse Distribution Channels In The U.S. & Japan! – Major Drivers,” the analysts discussed the first quarter 2024 financial results of Aflac Incorporated. The report highlighted a mix of encouraging and challenging outcomes, showcasing solid earnings with net earnings per diluted share at $3.25 and a 7.1% adjusted increase to $1.66, indicating robust profitability. With strong pretax profit margins of 32.8% in Japan and 21% in the U.S., the diligent management of expenses and underwriting played a significant role. Additionally, in Japan, the continuous flow of new and innovative products, including the latest medical insurance launch, aimed at younger populations, was noted.
A look at Aflac Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Aflac Inc shows a balanced outlook for the future. With a score of 3 across key factors like Value, Dividend, Growth, and Resilience, the company demonstrates stability and consistency in its operations. The Momentum score of 4 indicates a positive trend in the company’s market performance, possibly signaling strong investor interest and improving stock performance. Aflac Inc’s focus on providing supplemental insurance in the United States and Japan positions it well in the insurance industry.
Aflac Inc‘s strategic focus on accident/disability plans, cancer expense plans, and various other insurance offerings provides a diversified product portfolio that caters to the needs of individuals in different markets. This diversification, combined with its consistent financial performance as reflected in the Smart Scores, suggests a promising long-term outlook for the company. As Aflac Inc continues to enhance its market presence and expand its insurance offerings, investors may find value in its balanced approach to growth and stability.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
